Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: ARISAN THERAPEUTICS INC
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2021-09-28 to 2023-09-27
Current total value of award: $526793.52
Description: EXERCISE OPTIONAL 12 MONTH EFFORT FOR PHASE II SBIR R&D EFFORT TO EVALUATE ARN-75039 FOR DUAL EFFICACY AGAINST BOTH PARENTERAL AND AEROSOLIZED LASSA VIRUS INFECTION IN A GUINEA PIG MODEL.